Equities researchers at D. Boral Capital began coverage on shares of Context Therapeutics (NASDAQ:CNTX - Get Free Report) in a note issued to investors on Monday, MarketBeat reports. The brokerage set a "buy" rating and a $9.00 price target on the stock.
Separately, HC Wainwright reiterated a "buy" rating and set a $6.00 price target on shares of Context Therapeutics in a research report on Monday, September 23rd. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $6.80.
Get Our Latest Research Report on Context Therapeutics
Context Therapeutics Stock Performance
Context Therapeutics stock traded up $0.07 during midday trading on Monday, reaching $1.46. 331,550 shares of the stock were exchanged, compared to its average volume of 307,910. Context Therapeutics has a 52 week low of $0.77 and a 52 week high of $2.75. The firm has a market cap of $109.50 million, a PE ratio of -1.53 and a beta of 2.25. The company's fifty day moving average is $1.99 and its 200-day moving average is $2.08.
Context Therapeutics (NASDAQ:CNTX - Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.11). On average, sell-side analysts anticipate that Context Therapeutics will post -0.51 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Context Therapeutics
A number of large investors have recently added to or reduced their stakes in the company. Driehaus Capital Management LLC purchased a new position in shares of Context Therapeutics in the 2nd quarter worth about $4,527,000. Great Point Partners LLC bought a new stake in Context Therapeutics in the 2nd quarter worth approximately $14,876,000. Blue Owl Capital Holdings LP purchased a new stake in Context Therapeutics in the second quarter worth approximately $10,348,000. Nantahala Capital Management LLC bought a new position in Context Therapeutics during the second quarter valued at approximately $3,881,000. Finally, Renaissance Technologies LLC raised its stake in shares of Context Therapeutics by 63.4% during the second quarter. Renaissance Technologies LLC now owns 65,200 shares of the company's stock worth $131,000 after acquiring an additional 25,300 shares in the last quarter. Hedge funds and other institutional investors own 14.03% of the company's stock.
About Context Therapeutics
(
Get Free Report)
Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.
Further Reading
Before you consider Context Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Context Therapeutics wasn't on the list.
While Context Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
